Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City:
KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the first sustained virologic response1 (SVR)
results 12 weeks after completion of therapy (SVR12, considered
virologic cure) fromC-SURGE,
an ongoing, open label Phase 2 clinical trial evaluating MK-3682B
[uprifosbuvir (MK-3682)2/grazoprevir3/rusazvir4],
the company ’s investigational triple-combination therapy in
treatment-experienced patients with hepatitis C virus (HCV) genotype
(GT) 1 infection for whom treatmLanguage:
EnglishContact: MerckMedia:Doris Li, 908-740-1903Michael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news
More News: Antiviral Therapy | Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Politics | Urology & Nephrology | Virology